Pharmaceutical compositions and related methods
AssigneeHealor Ltd.
InventorsLiora BRAIMAN-WIKSMAN, Tamar TENNENBAUM, Inessa SOLOMONIK, Ofra LEVY-HACHAM, Ephraim BRENER
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions and methods for accelerating the healing process of wounds, increasing the closure of skin wounds, and decreasing inflammation at the site of a skin wound. Specifically, the disclosure relates to compositions comprising a delta-PKC activator, an alpha-PKC inhibitor, and a pharmaceutically acceptable carrier that is free of Ca2+ and Mg2+ cations. The disclosure also relates to compositions comprising an insulin or insulin analog and a pharmaceutically acceptable carrier that is free of Ca2+ and Mg2+ cations.
Claims19
1-116. (canceled)
A method for increasing the closure of a skin wound on an animal comprising the steps of:
- a) providing a pharmaceutical composition comprising a delta-PKC activator, an alpha-PKC inhibitor, and a pharmaceutically acceptable carrier that is free of Ca2+ and Mg2+ cations;
- and
- b) administering to a skin wound on an animal an effective amount of the pharmaceutical composition;
- whereby closure of the skin wound is increased.
A method for increasing the closure of a wound on an animal comprising the steps of:
- a) providing a pharmaceutical composition comprising a delta-PKC activator, and alpha-PKC inhibitor, and a pharmaceutically acceptable carrier that is free of Ca2+ and Mg2+ cations;
- and
- b) administering to a wound on an animal an effective amount of the pharmaceutical composition, wherein the wound is at least one selected from the group consisting of diabetic ulcer wounds, acral lick wounds, proud flesh wounds, surgical wounds, chronic solar abscess wounds, and osteomyelitis wounds;
- whereby closure of the wound is increased.
Dependencies are inferred from the claim text.